RetinAI Discovery
RetinAI
FDA clearedAMDgeographic atrophydiabetic retinopathyDMEglaucoma
Vendor-neutral platform that collects OCT and fundus data from multiple devices and layers on AI analysis; its OCT Atlas algorithm covers AMD, GA, DR, DME and glaucoma.
FDA clearance covers image management; AI outputs not confirmed within cleared indications.
- Company
- RetinAI
- Category
- Imaging analysis
- Reads
- OCT volumes, fundus images, DICOM and proprietary device formats
- Built for
- Clinics, hospitals, researchers, pharma
- Billing
- Check vendor
- Regulatory
- FDA 510(k) K211715 (Apr 28, 2022), product code NFJ (ophthalmic image management system). The K number covers image management; vendor says OCT Atlas is CE-marked for clinical use. Whether the AI biomarker outputs are within FDA-cleared indications was not confirmed. · source
- Last verified
- 2026-10-07
DotAEye is independent of RetinAI. Confirm indications, intended use, and clearance status with the manufacturer before clinical use.